The Road Ahead for Circulating microRNAs in Diagnosis and Management of Testicular Germ Cell Tumors

This publication has 17 references indexed in Scilit:

• Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer
  European Urology Oncology, 2021
• Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection
  European Urology, 2019
• MicroRNAs: Turning the Tide in Testicular Cancer
  European Urology, 2019
• Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study
  Journal of Clinical Oncology, 2019
• Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment
  BioMed Research International, 2019
• Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor
  Journal of Urology, 2018
• The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1
  Urologia Internationalis, 2018
• Serum tumor markers in the evaluation of male germ cell tumors
  Nature Reviews Urology, 2010
• American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors
  Journal of Clinical Oncology, 2010
• Retroperitoneal Metastases in Testicular Cancer: Role of CT Measurements of Residual Masses in Decision Making for Resection after Chemotherapy
  Radiology, 2000